Artificial Organs Market Research Report – Segmented By Technology (Mechanical Bionics, Electronic Bionics); Product (Artificial Organs, Artificial Bionics); and Region – Size, Share, Growth Analysis | Forecast (2024 – 2030)

Market Size and Overview:

According to our research report, the global artificial organs market is at USD 26.26 billion in 2023 and estimated to reach a total market valuation of USD 48.62 billion by 2030. The market is projected to grow with a CAGR of 9.2% per annum during the period of analysis.

An artificial organ refers to a medical device that is either implanted or integrated into the body to replicate or enhance the natural function of an organ. The scope of the report encompasses various artificial organs, including implanted devices like pacemakers, fully artificial hearts, and organ support systems such as dialysis and extracorporeal membrane oxygenation (ECMO) machines.

Organ failure primarily stems from factors such as blood loss, substance abuse, severe trauma, and acute disorders. Lifestyle choices like smoking, excessive alcohol consumption, poor diet, and lack of physical activity also significantly impact organ function. The advent of advanced artificial support systems and improvements in healthcare infrastructure is expected to drive the demand for bionics and artificial organs.

The increasing global elderly population is a significant driver for organ implants. Individuals aged over 65 are increasingly seeking organ transplants, with this demographic experiencing the highest demand for artificial devices due to their susceptibility to post-transplant complications. In 2021, it was estimated that 8,895 organ transplant procedures were performed on Americans over 65 (current estimates suggest 3,114 as of April 2022), highlighting the rising demand for artificial organs alongside increasing life expectancy and the need for organ donors.

The utilization of 3D bioprinting in creating artificial organs is pivotal in the field of organ transplantation, as it reduces the risk of organ rejection. Additionally, artificial intelligence is poised to revolutionize global trends in artificial devices, with several nations focusing on personalized assessments of organ and donor suitability. Such tools will assist patients in making informed decisions regarding organ acceptance or awaiting better alternatives.

Impact of COVID-19 on the Industry

The surge in global COVID-19 cases has escalated the market demand for COVID-19 vaccinations, leading to an increased need for rapid diagnostic tests. Real-time PCR (RT-PCR) has emerged as the most cost-effective and efficient method for COVID-19 diagnosis, as indicated by multiple studies. The imposition of strict lockdown measures following the sudden outbreak of the COVID-19 pandemic has resulted in the postponement of elective procedures to mitigate the risk of infection. Consequently, surgeons face greater challenges in meeting the requirements for infection-free operating rooms for artificial organ implants, adversely affecting the market.

Market Drivers

The market growth is propelled by the increasing prevalence of chronic diseases:

The rising incidence of chronic illnesses, driven by a growing population, serves as a key driver for market expansion. With the escalating instances of COVID-19, the market is projected to thrive from 2022 to 2030.

The scarcity of organ donors stimulates market growth:

The current shortage of organ donors necessitates patients to endure lengthy waits for organ transplantation. Artificial organs provide interim solutions, thereby driving market growth. Additionally, factors such as advancements in medical bionics, heightened public awareness of artificial organs, an aging population, growing popularity of home hemodialysis, and an uptick in accidents and severe injuries positively influence the artificial organ industry.

Market Restraints

The high cost of surgical procedures poses a restraint on the market:

Conversely, the market expansion is expected to be hindered by the high cost of surgeries and increasing public awareness of associated risks with artificial organs. Throughout the forecast period from 2022 to 2030, a shortage of skilled professionals is anticipated to pose a challenge to the artificial organ market.

Global Artificial Organs Market - By Product

Artificial Organs

  • Renal
  • Cardiac
  • Pulmonary
  • Hepatic
  • Pancreatic

Artificial Bionics

  • Cochlear Implants
  • Exoskeletons
  • Bionic Limbs
  • Visual Bionics
  • Neural Bionics

In 2021, artificial organs dominated the industry, holding a market share of approximately 70.9%. The market is witnessing expansion due to heightened demand for liver, heart, kidney, and lung transplants. In the United States, the median waiting time for a kidney transplant stands at 5 years, with various factors like body size, blood type, distance from a donor, and disease severity taken into consideration during the wait. Consequently, manufacturers are focusing on developing wearable artificial kidneys, bio-lungs, and artificial pancreases to address the challenge of unmet demand.

The segment of artificial bionics is projected to experience the fastest Compound Annual Growth Rate (CAGR) during the forecast period. The increasing demand for cochlear implants, visual enhancements, exoskeletons, artificial limbs, and neural bionics is driving market expansion. Favorable reimbursement policies and expedited FDA approvals for implants are further fueling market growth. For instance, in January 2022, the U.S. Food and Drug Administration approved Cochlear Limited's Cochlear Nucleus Implants for the treatment of single-sided deafness and unilateral hearing loss.

Global Artificial Organs Market - By Technology

  • Mechanical Bionics
  • Electronic Bionics

In 2021, mechanical bionics held a market share of 67.1%, emerging as the predominant technology. The prevalence of organ failure is increasing, driving the affordability of mechanical bionics. The demand for mechanical prosthetic heart valves is particularly high due to their extended durability compared to alternatives. Rapid FDA approvals and favorable reimbursement policies are additional factors contributing to market expansion. For instance, Abbott's Portico with FlexNav TAVR system received FDA approval in September 2021 for treating patients with symptomatic aortic stenosis who may be at high or very high risk for open-heart surgery.

During the forecast period, the electronic bionics category is expected to witness the fastest growth rate in the artificial organs and bionics market. According to Bionics Queensland, approximately 1.0 billion individuals globally live with a physical disability, with 190.0 million adults experiencing primary functional difficulties. However, logistical and financial barriers remain significant in many developing nations. For numerous individuals with disabilities, prosthetics such as artificial hands, limbs, and legs are their only option. These prostheses, powered by myoelectric batteries and electronic devices, can stimulate nerve movements through sensors. Sensory electronic technologies enable mobility in artificial organs, facilitated by advancements in machine learning, smart textiles, and component modeling. Factors such as an increase in traffic accidents, the rise in amputees, and individuals born without limbs are expected to drive the demand for electronic bionics.

Global Artificial Organs Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

North America led the market in 2022 with a share of 45.4%, expected to maintain dominance throughout the forecast period. The increasing prevalence of organ failure and the growing number of transplant surgeries are driving market expansion in the region. The presence of advanced healthcare facilities and numerous branches of renowned biotechnology and medical device companies like Zimmer Biomet, Arthrex, Inc., Medtronic, Novartis AG, and Stryker further contributes to its supremacy.

For instance, on March 10, 2022, Zimmer Biomet Holdings, Inc. introduced Walken, an AI-enhanced design that predicts patients' likelihood of experiencing reduced gait speed ninety days post-hip or knee surgery. Walken enhances ZBEdge, a suite of integrated smart, robotic technologies designed to provide transformative data-driven clinical insights to improve patient outcomes.

The past five years have witnessed significant growth in organ donors in the U.S., with a 27.7% increase between 2015 and 2019, according to the U.S. Department of Health and Human Services. The rising demand for kidney transplants is a key factor driving the artificial organs and bionics market, with kidney transplants increasing from 16,186 in 2011 to 24,670 in 2021.

In the Asia-Pacific region, rapid economic growth in countries like Japan, China, and India is expected to drive market expansion at the fastest rate during the forecast period. These countries have large populations and high prevalence of chronic diseases, contributing to the growth of artificial organs and bionic devices. Investments such as the USD 210 million received by Micro Life Sciences Pvt Ltd. from Warburg Pincus in February 2022 are expected to bolster the growth of domestic medical device companies, enhancing their global presence and scaling up clinical research efforts.

These nations offer advanced surgical procedures and are witnessing a surge in medical tourism due to the affordability of surgical treatments. Consequently, the increase in medical tourism and the prevalence of chronic diseases leading to organ failure are major drivers of market expansion in the region.

Global Artificial Organs Market - By Companies

  • Zimmer Biomet
  • Medtronic
  • Abbott
  • ABIOMED, INC
  • Berlin Heart GmbH
  • Biomet, Inc
  • Boston Scientific Corporation
  • Edwards Lifesciences Corporation
  • Ekso Bionics
  • HeartWare International, Inc
  • iWalk, Inc.
  • Jarvik Heart, Inc
  • SynCardia Systems, LLC.

Recent Developments in the Global Artificial Organs Market

Regulatory Approval:

  • In 2021, Abbott's smallest mechanical heart valve received FDA approval for treating infants and young children requiring mitral and aortic heart valves.

Chapter 1. Global Artificial Organs Market – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. Global Artificial Organs Market – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

       2.3.1. Impact during 2023 - 2030

       2.3.2. Impact on Supply – Demand

Chapter 3. Global Artificial Organs Market – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. Global Artificial Organs Market Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. Global Artificial Organs Market - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. Global Artificial Organs Market – By Product

6.1. Artificial Organs

6.1.1 Kidney

6.1.2 Heart

6.1.3 Lungs

6.1.4 Liver

6.1.5 Pancreas

6.2. Artificial Bionics

6.2.1 Cochlear implant

6.2.2 Exoskeleton

6.2.3 Bionic limbs

6.2.4 Vision bionics

6.2.5 Brain bionics

Chapter 7. Global Artificial Organs Market – By Technology

7.1. Mechanical bionics

7.2. Electronic bionics

Chapter 8. Global Artificial Organs Market- By Region

8.1. North America

8.2. Europe

8.3. Asia-Pacific

8.4. Latin America

8.5. The Middle East

8.6. Africa

Chapter 9. Global Artificial Organs Market - key players

9.1. Zimmer Biomet

9.2. Medtronic

9.3. Abbott

9.4. ABIOMED, INC

9.5. Berlin Heart Gmbh

9.6. Biomet, Inc

9.7. Boston Scientific Corporation

9.8. Edward Lifesciences Corporation

9.9. Ekso Bionics

9.10. Heartware International, Inc

9.11. Iwalk, Inc.

9.12. Jarvik Heart, Inc

9.13. SynCardia Systems, LLC.

Download Sample

5471

The field with (*) is required.

Choose License Type

$

2850

$

5250

$

4500

$

1800